Latest filing published 19 Feb 2025 for Acrivon Therapeutics, Inc., €2,248.
Insider track record
Rasmus Holm-Jorgensen: trading record in brief
All filings by Rasmus Holm-Jorgensen on record concern Acrivon Therapeutics, Inc. Between 14 November 2022 and 14 February 2025, the trades on record add up to 8 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The latest filing, published on 19 February 2025, reports a share grant of €2,248 in Acrivon Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Rasmus Holm-Jorgensen
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 434 shares@ US$5.424.5% of flowCommon StockSEC:0000905148-25-000728:0
- 368 shares@ US$7.925.5% of flowCommon StockSEC:0000905148-24-003226:0
- 368 shares@ US$7.024.7% of flowCommon StockSEC:0000905148-24-002280:0
- 368 shares@ US$8.365.7% of flowCommon StockSEC:0000905148-24-001489:0
- 434 shares@ US$3.402.8% of flowCommon StockSEC:0000905148-24-000763:0
- 1,470 shares@ US$5.0813.9% of flowCommon StockSEC:0000905148-23-001475:0
- 9,500 shares@ US$3.6362.9% of flowCommon StockSEC:0001140361-23-030544:0
- 20,030 shares0Common StockSEC:0001209191-22-057398:0
8 of 8 declarations
